ACTINIUM PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ACTINIUM PHARMACEUTICALS, INC. (ATNM) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.21 million as of 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2022-03-25
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.21M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.69M.
- 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.42M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $1.42M.
- 2018-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.95M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2021-12-31 | $1.21M 10-K · filed 2022-03-25 | |
| 2020-12-31 | $1.69M 10-K · filed 2022-03-25 | |
| 2019-12-31 | $1.42M 10-K · filed 2021-03-31 | $1.42M 10-K · filed 2020-05-08 |
| 2018-12-31 | $2.95M 10-K · filed 2020-05-08 | |
| 2017-12-31 | $3.73M 10-K · filed 2019-03-15 | |
| 2016-12-31 | $8.08M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $6.20M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $1.66M 10-K · filed 2014-02-28 | |
| 2012-12-31 | $1.50M 10-K · filed 2014-02-28 | |
| 2011-12-31 | $741.42K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |